More than 70 years researching and improving health

 

1946

Foundation of the Company

 

1981

Beginning of research into
low-molecular-weight heparins

 

1998

Launch of Bemiparin on the
Spanish market and start-up of
cooperations in Portugal

 

2002

Internationalization of ROVI® following
approval of Bemiparin outside Spain

 

2003

Increased International coverage
to 59 countries

 

2006

Construction of the Granada R&D&i
centre and plant

 

2007

Agreement with Laboratoires Servier
for the marketing of Corlentor®

 

2009

Strategic agreement with Merck
Sharp & Dhome (MSD)

 

2011

Agreement with MSD for the marketing of
Vitorin® and Absorcol®

 

2012

FDA certification of the
injectables plant

 

2013

Agreements to market products
from Novartis and Medice

 

2014

registration process for an
enoxaparin biosimilar with the EU

 

2015

Adquisition of the new injectables plant
in San Sebastián de los Reyes

Successful completion
of PRISMA-2 study

Agreement with Astellas for the
marketing of Volutsa®

 

2016

Agrement with Novartis for the marketing
of Neparvis®
and Orexigen for the
marketing of Mysimba®

 

2017

Successful completion of the
procedure to apply for authorization
to market an exoparin biosimilar in 26 UE countries